Sort by

Send to

Choose Destination

Search results

Items: 4


The deleterious influence of tenofovir-based therapies on the progression of atherosclerosis in HIV-infected patients.

Aragonès G, Pardo-Reche P, Fernández-Sender L, Rull A, Beltrán-Debón R, Rodríguez-Gallego E, Camps J, Joven J, Alonso-Villaverde C.

Mediators Inflamm. 2012;2012:372305. doi: 10.1155/2012/372305. Epub 2012 May 7.


Serum paraoxonase-3 concentration in HIV-infected patients. Evidence for a protective role against oxidation.

Aragonès G, García-Heredia A, Guardiola M, Rull A, Beltrán-Debón R, Marsillach J, Alonso-Villaverde C, Mackness B, Mackness M, Pedro-Botet J, Pardo-Reche P, Joven J, Camps J.

J Lipid Res. 2012 Jan;53(1):168-74. doi: 10.1194/jlr.P018457. Epub 2011 Oct 14.


Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 polymorphism.

Aragonès G, Alonso-Villaverde C, Pardo-Reche P, Rull A, Beltrán-Debón R, Rodríguez-Gallego E, Fernández-Sender L, Camps J, Joven J.

BMC Med Genet. 2011 Sep 22;12:120. doi: 10.1186/1471-2350-12-120.


Host-pathogen interactions in the development of metabolic disturbances and atherosclerosis in HIV infection: the role of CCL2 genetic variants.

Alonso-Villaverde C, Aragonès G, Beltrán-Debón R, Fernández-Sender L, Rull A, Rodríguez-Sanabria F, Marsillach J, Pardo-Reche P, Camps J, Joven J.

Cytokine. 2010 Sep;51(3):251-8. doi: 10.1016/j.cyto.2010.05.008. Epub 2010 Jun 22.


Supplemental Content

Loading ...
Support Center